Ensign Peak Advisors
BCAX

Ensign Peak Advisors’s Bicara Therapeutics BCAX Stock Holding History

Ensign Peak Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Sell
342,211
-59,233
-15% -$1.32M 0.02% 432
2026
Q1 		$7.98M Hold
401,444
– – 0.01% 452
2025
Q4 		$6.76M Buy
+401,444
New +$6.86M 0.01% 478

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ensign Peak Advisors's BCAX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Bicara Therapeutics (BCAX) stake by 15% in Q2 2026, selling an estimated $1.32M and leaving 342,211 shares worth $10.2M. The position accounts for 0.02% of the portfolio, ranked #432.

Ensign Peak Advisors first reported a position in BCAX in Q4 2025 and has held it in 3 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Ensign Peak Advisors held 342,211 shares of Bicara Therapeutics worth $10.2M as of Q2 2026.
  • Ensign Peak Advisors sold 59,233 Bicara Therapeutics shares in Q2 2026, an estimated $1.32M.
  • Bicara Therapeutics made up 0.02% of Ensign Peak Advisors's portfolio in Q2 2026, its #432 holding.
  • Ensign Peak Advisors first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.